LEADER 05998nam 2200661Ia 450 001 9910163020803321 005 20200520144314.0 010 $a1-283-15375-0 010 $a9786613153753 010 $a3-8055-9530-1 035 $a(CKB)3170000000004979 035 $a(EBL)3016390 035 $a(SSID)ssj0000542987 035 $a(PQKBManifestationID)12243519 035 $a(PQKBTitleCode)TC0000542987 035 $a(PQKBWorkID)10518828 035 $a(PQKB)11343122 035 $a(MiAaPQ)EBC3016390 035 $a(OCoLC)664346560 035 $a(SZ-BaSKA)254200 035 $a(EXLCZ)993170000000004979 100 $a20100615d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAnti-VEGF /$fvolume editors, F. Bandello, M. Battaglia Parodi ; co-editors, A.J. Augustin ... [et al.] 210 $aBasel ;$aNew York $cKarger$dc2010 215 $a1 online resource (155 p.) 225 0 $aDevelopments in ophthalmology,$x0250-3751 ;$vv. 46 300 $aDescription based upon print version of record. 311 $a3-8055-9529-8 320 $aIncludes bibliographical references and indexes. 327 $a""Cover""; ""Contents""; ""List of Contributors""; ""Preface""; ""Angiostatic and Angiogenic Factors""; ""Abstract""; ""Angiostatic Factors in the Eye""; ""Angiogenic Factors""; ""Mechanisms of Ocular Angiogenesis and Its Molecular Mediators""; ""Abstract""; ""Angiogenesis: Mechanisms and Molecular Mediators""; ""Retinal Circulation""; ""Pathological Ocular Angiogenesis""; ""References""; ""Antivascular Endothelial Growth Factors in Age-Related Macular Degeneration""; ""Abstract""; ""Pegaptanib""; ""Bevacizumab""; ""Ranibizumab""; ""PIER Study""; ""FOCUS Study""; ""MARINA Study"" 327 $a""ANCHOR Study""""PrONTO Study""; ""New Anti-VEGF Treatments for Neovascular Age-Related Macular Degeneration""; ""Imaging Anti-VEGF Effects on Retinal Morphology in Age-Related Macular Degeneration""; ""References""; ""Antivascular Endothelial Growth Factor in Diabetic Retinopathy""; ""Abstract""; ""Role of the Vascular Endothelial Growth Factor in Diabetic Retinopathy""; ""Anti-VEGF Therapy in the Treatment of Diabetic Macular Edema and Proliferative Diabetic Retinopathy""; ""Ranibizumab""; ""Pegaptanib""; ""Bevacizumab""; ""VEGF Trap""; ""Bevasiranib""; ""Rapamycin""; ""Conclusion"" 327 $a""References""""Retinal Vein Occlusions""; ""Abstract""; ""Background""; ""Pathogenesis and Risk Factors""; ""Symptoms and Natural Course""; ""Treatment of RVO""; ""Conclusion""; ""References""; ""Antivascular Endothelial Growth Factor for Choroidal Neovascularization in Pathologic Myopia""; ""Abstract""; ""Natural History""; ""Treatment Options""; ""Anti-VEGF for Myopic CNV""; ""Subfoveal Myopic CNV""; ""Juxtafoveal Myopic CNV""; ""References""; ""Antivascular Endothelial Growth Factors for Inflammatory Chorioretinal Disorders""; ""Abstract"" 327 $a""Multifocal Choroiditis and Punctate Inner Choriodopathy""""Ocular Histoplasmosis Syndrome""; ""BehA?eta???s Disease""; ""Multiple Evanescent White Dot Syndrome""; ""Birdshot Chorioretinopathy""; ""Acute Multifocal Posterior Placoid Pigment Epitheliopathy""; ""Serpiginous Choroiditis""; ""Persistent Placoid Maculopathy""; ""Uveitic Cystoid Macular Edema""; ""Conclusions""; ""References""; ""Antivascular Endothelial Growth Factor Treatment in Pseudoxanthoma Elasticum Patients""; ""Abstract""; ""History and General Disease""; ""Genetics of PXE""; ""Ocular Signs and Symptoms of PXE"" 327 $a""Treatment of CNV""""Conclusions""; ""References""; ""Antivascular Endothelial Growth Factor in Hereditary Dystrophies""; ""Abstract""; ""Besta???s Dystrophy""; ""Pattern Dystrophy""; ""Retinitis Pigmentosa""; ""Fundus Flavimaculatus""; ""Sorsby Fundus Dystrophy""; ""References""; ""Antivascular Endothelial Growth Factor as an Approach for Macular Edema""; ""Abstract""; ""Basic Pathophysiologic Mechanisms""; ""Major Pathologic Conditions Leading to ME: Retinal Vascular Disease""; ""Pharmacologic Treatment Options in ME with a Focus on Anti-VEGF Therapies""; ""ME Secondary to CRVO and BRVO"" 327 $a""References"" 330 $aThe development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability. The advantages over conventional laser photocoagulation are evident as laser treatment always leaves scars and causes a retinal sensitivity deterioration. Starting with an outline of treatment principles, this volume covers all aspects of anti-VEGF therapy for ophthalmological disorders. In particular, specific chapters are dedicated to age-related macular degeneration, degenerative myopia, angioid streaks, inflammatory diseases, hereditary dystrophies, retinal vein occlusion, diabetic retinopathy, ocular tumors, as well as anterior segment neovascularization. The book gives an update on the application of anti-VEGF in ocular diseases to general ophthalmologists as well as retina specialists. 410 0$aDevelopments in Ophthalmology 517 3 $aAnti-vascular endothelial growth factors 606 $aEye$xBlood-vessels$xDiseases$xChemotherapy 606 $aVascular endothelial growth factors$xAntagonists$xTherapeutic use 615 0$aEye$xBlood-vessels$xDiseases$xChemotherapy. 615 0$aVascular endothelial growth factors$xAntagonists$xTherapeutic use. 676 $a617.7/061 701 $aBandello$b F$g(Francesco)$01208632 701 $aBattaglia Parodi$b M$g(Maurizio)$01208633 701 $aAugustin$b A. J$01208634 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910163020803321 996 $aAnti-VEGF$92788458 997 $aUNINA